Charles Conover is SVP & R&D Program Management at ENZON PHARMACEUTICALS INC (ENZN). They have made 1 open-market trade across 1 company since 2012, most recently 2013-01-23.
CIK 0001538563
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ENZN | 74,793 | $3.4M |
Shares reported on the most recent Form 4, priced at the 2013-01-25 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ENZN | SELL | 2012-06-05 | 2012-06-06 | $6.78 | $170K | -11.7% | -7.1% | -7.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.